Idelvion (Albutrepenonacog Alfa)

Albutrepenonacog alfa provides exogenous factor VIII, restoring the missing clotting protein in the intrinsic coagulation pathway. This enables the formation of a stable fibrin clot, correcting the bleeding tendency characteristic of hemophilia A.

The dose of Idelvion is individualized by the prescribing physician based on the patient’s weight, severity of hemophilia, and clinical situation. Dosing regimens are determined during a medical consultation and are not standardized.

Safety data for Idelvion in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Idelvion, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Idelvion is a recombinant, extended‑half‑life factor VIII product, offering less frequent infusions compared with standard factor VIII concentrates. Its molecular design provides prolonged plasma persistence while maintaining comparable efficacy and safety profiles to other approved recombinant factor VIII therapies.

Idelvion must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If temperature excursions occur, discard the product according to the supplier’s guidelines.

Idelvion is given by intravenous infusion. The healthcare professional prepares the solution according to aseptic technique, administers it over the recommended time, and monitors the patient for any infusion‑related reactions during and after the infusion.

The most serious risks include development of neutralizing inhibitors against factor VIII, which can reduce efficacy, and rare hypersensitivity reactions such as anaphylaxis. Thromboembolic events, though uncommon, may also occur and require immediate medical attention.

Idelvion is contraindicated in patients with known hypersensitivity to albutrepenonacog alfa or any of its excipients. Individuals with a history of severe inhibitor formation against factor VIII should also avoid its use unless specifically advised by a hematology specialist.